A Novel Antidote-Controlled Anticoagulant Reduces Thrombin Generation and Inflammation and Improves Cardiac Function in Cardiopulmonary Bypass Surgery
Open Access
- 1 September 2006
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 14 (3), 408-415
- https://doi.org/10.1016/j.ymthe.2006.04.006
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary BypassAnesthesia & Analgesia, 2002
- Inflammation–coagulation network: are serine protease receptors the knot?Trends in Pharmacological Sciences, 2000
- Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypassThe Journal of Thoracic and Cardiovascular Surgery, 1999
- Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypassThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dogThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Heparin‐induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseasesBritish Journal of Haematology, 1997
- Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypassThe Annals of Thoracic Surgery, 1994
- Characterization of Prothrombin Activation during Cardiac Surgery by Hemostatic Molecular MarkersAnesthesiology, 1994
- Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric OxideScience, 1992